U.S. Markets closed

PolyPid Ltd. (PYPD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.27+0.23 (+3.34%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.03
Bid6.85 x 1100
Ask7.65 x 1800
Day's Range7.00 - 7.28
52 Week Range6.95 - 16.50
Avg. Volume26,770
Market Cap136.183M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMay 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.50
  • Simply Wall St.

    We're Keeping An Eye On PolyPid's (NASDAQ:PYPD) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although

  • GlobeNewswire

    PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

    PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT. In her presentation, Dikla Czaczkes Akselbrad, Polypid’s EVP and CFO will provide corporate highlights and discuss recent

  • Benzinga

    PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor

    PolyPid Ltd (NASDAQ: PYPD) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents. OncoPLEX induced strong inhibition of tumor growth and recurrence in a partially resected human glioblastoma subcutaneous mouse model. A single local OncoPLEX application induced 98% tumor growth inhibition (day 4